Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | STAT1 | P42224 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | SMO | Q99835 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | MTTP | P55157 | 2/20 | 0.41 |
| ▸ | APOB | P04114 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501350 | 0.91 | NPC1 (0.46) | NPC1RAB9AKDM4ESTAT1SMN1; SMN2 | |
| SCHEMBL6503326 | 0.91 | SMO (0.54) | NPC1RAB9AKDM4ESTAT1SMO | |
| SCHEMBL6795866 | 0.86 | NPC1 (0.53) | NPC1RAB9AKDM4ESTAT1SMN1; SMN2 | |
| SCHEMBL6492713 | 0.85 | MTTP (0.41) | NPC1RAB9AKDM4ESTAT1SMN1; SMN2 | |
| SCHEMBL6492083 | 0.83 | SMO (0.54) | SMOTP53MTTPAPOBLMNA | |
| SCHEMBL6499732 | 0.82 | NPC1 (0.51) | NPC1RAB9AKDM4ESTAT1SMN1; SMN2 | |
| SCHEMBL6502168 | 0.82 | NPC1 (0.51) | NPC1RAB9AKDM4ESTAT1SMN1; SMN2 | |
| SCHEMBL6488749 | 0.82 | MTTP (0.52) | NPC1RAB9AKDM4ESMN1; SMN2MAPT | |
| SCHEMBL6495706 | 0.81 | TP53 (0.58) | KDM4ESMN1; SMN2MAPTSMOTP53 | |
| SCHEMBL6501450 | 0.80 | NPC1 (0.43) | NPC1RAB9AKDM4ESTAT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | NPC1 100/4885RAB9A 4382/4885KDM4E 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.